Bristol Myers Squibb Co BMY
Bristol Myers Squibb Co (NYSE: BMY) is an oncology drug developer. Its lead program, Marketed portfolio (Opdivo, Eliquis, Reblozyl, Breyanzi, Camzyos, Cobenfy, others), is in Phase 3 for oncology, hematology, immunology, cardiovascular, neuroscience. Its next catalyst on record is Reblozyl: PDUFA date, sBLA for MF-associated anemia (March 11, 2027).
Upcoming catalysts
- March 11, 2027Reblozyl — PDUFA date, sBLA for MF-associated anemia
The FDA granted a PDUFA date of March 11, 2027.
- May 13, 2027mezigdomide — PDUFA date, NDA for MeziKd in RRMM
The FDA has granted a PDUFA date of May 13, 2027 for this indication.
Next further out: Registrational programs (AR LDD, Sotyktu SLE/SjS, admilparant, milvexian, Cobenfy, arlo-cel, iberdomide, others) — Registrational study readouts (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Reblozyl sNDA/sBLA (MF-associated anemia) | myelofibrosis-associated anemia | protein/peptide | Approved |
| Camzyos sNDA (adolescents) | symptomatic obstructive HCM, ages 12-<18 | small molecule | Approved |
| iberdomide | relapsed/refractory multiple myeloma (RRMM) | small molecule | Phase 3 |
| mezigdomide + carfilzomib/dexamethasone (MeziKd) | RRMM | small molecule | Phase 3 |
| milvexian (with J&J) | atrial fibrillation; secondary stroke prevention | small molecule | Phase 3 |
| admilparant | IPF; progressive pulmonary fibrosis | small molecule | Phase 3 |
| Cobenfy (additional indications) | Alzheimer's disease psychosis; bipolar-I | small molecule | Phase 3 |
| arlo-cel | 4L+ multiple myeloma | cell therapy | Phase 3 |
| pumitamig (BNT327, with BioNTech) | NSCLC and other solid tumors | antibody | Phase 3 |
| iza-bren (with SystImmune) | TNBC, ESCC, NSCLC | antibody | Phase 3 |
| golcadomide | follicular lymphoma, LBCL | small molecule | Phase 3 |
| RYZ101 | SSTR2+ GEP-NETs | radiopharmaceutical | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Summit Therapeutics Inc. SMMT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.